103 CARNEGIE CENTER, PRINCETON, NJ
Investor Presentation
Provides Regulatory Update on New Drug Application for GTx-104
Announces Third Quarter 2026 Financial Results, Provides Business Update
News, Material Contracts
Announces Second Quarter 2026 Financial Results, Provides Business Update
Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review.
Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104
Shareholder votes
Q3
Amended Quarterly Report
Q2
Q1
FY 2025
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
S-8 POS